Your Shopping Cart
By using this site you agree to our use of cookies. Please refer to our privacy policy for more information. Close
FDA’s 515 Program Initiative
- Date: January 27, 2011
- Source: Admin
FDA regulates medical devices and places them under one of the three classes, viz., Class I, Class II and Class III, based on the level of risk they carry. Class I and Class II devices are generally regarded as low-risk devices. They require FDA Clearance of an application called Premarket Notification ((or 510(k)) if the device is to be permitted to be sold in US. Class III devices, which tend to be high-risk devices and first-of-a-kind devices, require FDA Approval in the form of a Premarket Approval (PMA) Application.
When the medical device regulation program was introduced in the late 1970s, the FDA regulated 100 plus Class III device types through the 510(k) program. It was felt that FDA’s regulation would be temporary and over time, the FDA would reclassify those device types into Class I or II, or sustain the classification in Class III and call for PMA applications.
The process of reclassification is described in FDA’s regulations in Section 515 of the Federal Food, Drug and Cosmetic Act. Over the years, FDA has made progress in this original list; as of 2009, 26 medical device regulations remained in this transitional state awaiting final classification. In 2009, FDA kicked off the 515 Program Initiative to facilitate the final adjudication of these remaining Class III device types.
515 Process Steps
FDA takes the following five steps for each medical device type:
- collect existing scientific information in the public domain and/or from scientific experts;
- assess the risks versus benefits, and the clarity of knowledge of the medical device type subject to the reclassification;
- issue a proposed rule of the device type into Class I, II, or III;
- receive and review comments submitted by the public;
- issue a final rule on the device type to Class I, II, or III.
Source:
http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHTransparency/ucm240310.htm
Compliance Trainings
How FDA trains its investigators to review CAPA and what should you do to prepare
By - Jeff Kasoff
On Demand Access Anytime
By - Jeff Kasoff
On Demand Access Anytime
Excel Spreadsheets; Ensuring Data Integrity and 21 CFR Part 11 Compliance
By - David Nettleton
Live January 21, 2025
By - David Nettleton
Live January 21, 2025
Water System Investigation "How-To's" and Example Case Studies
By - T.C Soli
On Demand Access Anytime
By - T.C Soli
On Demand Access Anytime
Solutions for Addressing Fungal and Bacterial Spore Outbreaks in Pharmaceutical, Biotech, and Medical Device Operations
By - Jim Polarine
On Demand Access Anytime
By - Jim Polarine
On Demand Access Anytime
Compliance Standards
Best Sellers
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
-
By: Miles HutchinsonAdd to CartPrice: $249
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
-
San Francisco, CA | Aug 6-7, 2020
-
Virtual Seminar | Jul 16-17, 2020
-
Virtual Seminar | Jun 18-19, 2020
-
Los Angeles, CA | Aug 20-21, 2020
-
Virtual Seminar | Jul 16-17, 2020
-
Virtual Seminar | Jun 25-26, 2020
-
Virtual Seminar | Jun 10, 2020
-
Virtual Seminar | Jun 3-4, 2020
-
Virtual Seminar | Jul 6-7, 2020
-
San Francisco, CA | Oct 22-23, 2020
-
Virtual Seminar | Jul 9-10, 2020
-
Virtual Seminar | Jun 3-4, 2020
-
Virtual Seminar | June 3-4, 2020
-
Miami, FL | Jul 29-31, 2020
-
Virtual Seminar | Jun 17, 2020
-
Provider: ANSIAdd to CartPrice: $142
- Add to Cart
- Add to Cart
- Add to Cart
-
Provider: ANSIAdd to CartPrice: $120
-
Provider: ANSIAdd to CartPrice: $250
-
Provider: SEPTAdd to CartPrice: $299
- Add to Cart
-
Provider: Quality-Control-PlanAdd to CartPrice: $37
- Add to Cart
-
Provider: At-PQCAdd to CartPrice: $397
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
You Recently Viewed